<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02089737</url>
  </required_header>
  <id_info>
    <org_study_id>183-011</org_study_id>
    <secondary_id>JapicCTI-132374</secondary_id>
    <secondary_id>JapicCTI-R140654</secondary_id>
    <nct_id>NCT02089737</nct_id>
  </id_info>
  <brief_title>Panitumumab for Intravenous Infusion 100 mg and 400 mg Special Drug Use Surveillance &quot;Survey on Unresectable, Advanced or Recurrent Colorectal Cancer With Wild-type KRAS Gene&quot; (All-patient Surveillance)</brief_title>
  <official_title>Vectibix for Intravenous Infusion 100 mg and 400 mg Special Drug Use Surveillance &quot;Survey on Unresectable, Advanced or Recurrent Colorectal Cancer With Wild-type KRAS Gene&quot; (All-patient Surveillance)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The efficacy and safety of panitumumab (Vectibix) in the routine clinical setting will be
      studied.

      Specifically, information will be collected on the following as events of interest: skin
      disorders, interstitial lung disease, infusion reactions, electrolyte abnormalities, and
      cardiac disorders.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The efficacy and safety of panitumumab (Vectibix) in the routine clinical setting will be
      studied.

      Participants of this surveillance will be patients with unresectable, advanced or recurrent
      colorectal cancer with the wild-type KRAS gene. The planned sample size is 2,000 patients.

      The usual adult dosage is 6 mg/kg of panitumumab given by intravenous drip infusion over a
      60-minute period once every 2 weeks. The dosage may also be reduced as needed, depending on
      the patient's condition.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2010</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Adverse Drug Reactions</measure>
    <time_frame>Baseline through Week 42</time_frame>
    <description>The number of participants with adverse drug reactions reported during the observation period were tabulated by type, seriousness, and time of onset. . Adverse events are defined as any unfavorable and unintended sign, symptom or disease temporally associated with the use of a medicinal product reported from first dose of study drug to the last dose of study drug.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival</measure>
    <time_frame>Up to Week 42 or death (whichever occurred first)</time_frame>
    <description>Progression-free Survival (PFS) was defined as the time from the first day of study treatment to documented disease progression or death on study. For participants who experienced no disease progression and did not die while on study, data were censored at the date of the last tumor assessment. Kaplan-Meier methodology was used to estimate PFS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Up to Week 42 or death (whichever occurred first)</time_frame>
    <description>Overall survival was defined as the time to death from the start of panitumumab administration was tabulated.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">3091</enrollment>
  <condition>Advanced or Recurrent Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Panitumumab 6 mg/kg</arm_group_label>
    <description>Panitumumab 6 mg/kg, intravenous drip infusion over a 60-minute period, once every 2 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Panitumumab</intervention_name>
    <description>Panitumumab for intravenous infusion</description>
    <arm_group_label>Panitumumab 6 mg/kg</arm_group_label>
    <other_name>Vectibix</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Unresectable, advanced or recurrent colorectal cancer with wild-type KRAS gene
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Unresectable, advanced or recurrent colorectal cancer with wild-type KRAS gene

        Exclusion Criteria:

          -  Patients with a medical history of severe hypersensitivity to any of the ingredients
             of Vectibix
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Postmarketing Group Manager</last_name>
    <role>Study Chair</role>
    <affiliation>Takeda</affiliation>
  </overall_official>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 13, 2014</study_first_submitted>
  <study_first_submitted_qc>March 13, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 18, 2014</study_first_posted>
  <results_first_submitted>April 20, 2015</results_first_submitted>
  <results_first_submitted_qc>February 21, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">April 6, 2017</results_first_posted>
  <last_update_submitted>February 21, 2017</last_update_submitted>
  <last_update_submitted_qc>February 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants enrolled during the period from June 1, 2010 to November 14, 2010 were surveyed.</recruitment_details>
      <pre_assignment_details>Surveyed participants had a clinical diagnosis of wild-type KRAS unresectable advanced/recurrent colorectal cancer.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Panitumumab</title>
          <description>Panitumumab 6 mg/kg, intravenous drip infusion over a 60-minute period, once every 2 weeks for up to 42 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3091"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3085"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Survey form not completed</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not treated</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>3086 participants completed the survey form (5 participants did not complete it). 3085 participants were included in the safety analysis set after excluding 1 participant due to missing panitumumab treatment and AE data. From that set, 3084 participants were included in the efficacy analysis set after excluding 1 participant with missing data.</population>
      <group_list>
        <group group_id="B1">
          <title>Panitumumab</title>
          <description>Panitumumab 6 mg/kg, intravenous drip infusion over a 60-minute period, once every 2 weeks for up to 42 weeks</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3085"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt; 75 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2582"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;= 75 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="503"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1120"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1965"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3085"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Japan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3085"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>KRAS genotype</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Wild type</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3003"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-measurable/non-assessable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mutant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not determined</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Treatment stage (excluding posteroperative adjuvant chemotherapy)</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>First-line</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="310"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Second-line</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="543"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Third-line or later</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2232"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Eastern Cooperative Oncology Group Performance Status (ECOG-PS) at baseline</title>
          <description>ECOG-PS is measured on 6-point scale to assess participant's performance status. 0=Fully active, able to carry on all pre-disease activities without restriction; 1=Restricted in physically strenuous activity, but ambulatory and able to carry out light or sedentary work; 2=Ambulatory (&gt;50% of waking hours), capable of all selfcare, but unable to carry out any work activities; 3=Capable of only limited selfcare, confined to bed or chair more than 50% of waking hours; 4=Completely disabled, cannot carry on any selfcare, totally confined to bed or chair; 5=Dead.</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>PS:0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1877"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PS:1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="942"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PS:2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="241"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PS:3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PS:4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Metastatic lesions/sites of relapse</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3046"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Adverse Drug Reactions</title>
        <description>The number of participants with adverse drug reactions reported during the observation period were tabulated by type, seriousness, and time of onset. . Adverse events are defined as any unfavorable and unintended sign, symptom or disease temporally associated with the use of a medicinal product reported from first dose of study drug to the last dose of study drug.</description>
        <time_frame>Baseline through Week 42</time_frame>
        <population>Of the 3086 participants who completed the survey form, 3085 participants were included in the safety analysis set after excluding 1 participant for whom information regarding panitumumab treatment and adverse events were missing.</population>
        <group_list>
          <group group_id="O1">
            <title>Panitumumab</title>
            <description>Panitumumab 6 mg/kg, intravenous drip infusion over a 60-minute period, once every 2 weeks for up to 42 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Drug Reactions</title>
          <description>The number of participants with adverse drug reactions reported during the observation period were tabulated by type, seriousness, and time of onset. . Adverse events are defined as any unfavorable and unintended sign, symptom or disease temporally associated with the use of a medicinal product reported from first dose of study drug to the last dose of study drug.</description>
          <population>Of the 3086 participants who completed the survey form, 3085 participants were included in the safety analysis set after excluding 1 participant for whom information regarding panitumumab treatment and adverse events were missing.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3085"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Frequency of adverse drug reactions</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2595"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MedDRA SOC: Skin and subcutaneous tissue disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2364"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MedDRA SOC: Infections and infestations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="771"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MedDRA SOC: Gastrointestinal disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="642"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MedDRA SOC: Metabolism and nutrition disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="552"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MedDRA SOC: Cardiac disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression-free Survival</title>
        <description>Progression-free Survival (PFS) was defined as the time from the first day of study treatment to documented disease progression or death on study. For participants who experienced no disease progression and did not die while on study, data were censored at the date of the last tumor assessment. Kaplan-Meier methodology was used to estimate PFS.</description>
        <time_frame>Up to Week 42 or death (whichever occurred first)</time_frame>
        <population>Participants who were included in the efficacy analysis set and received panitumumab monotherapy as a third-line or later therapy.</population>
        <group_list>
          <group group_id="O1">
            <title>Panitumumab</title>
            <description>Panitumumab 6 mg/kg, intravenous drip infusion over a 60-minute period, once every 2 weeks for up to 42 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival</title>
          <description>Progression-free Survival (PFS) was defined as the time from the first day of study treatment to documented disease progression or death on study. For participants who experienced no disease progression and did not die while on study, data were censored at the date of the last tumor assessment. Kaplan-Meier methodology was used to estimate PFS.</description>
          <population>Participants who were included in the efficacy analysis set and received panitumumab monotherapy as a third-line or later therapy.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1061"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5" lower_limit="3.3" upper_limit="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <description>Overall survival was defined as the time to death from the start of panitumumab administration was tabulated.</description>
        <time_frame>Up to Week 42 or death (whichever occurred first)</time_frame>
        <population>All participants that received panitumumab monotherapy as a third-line or later therapy.</population>
        <group_list>
          <group group_id="O1">
            <title>Panitumumab</title>
            <description>Panitumumab 6 mg/kg, intravenous drip infusion over a 60-minute period, once every 2 weeks for up to 42 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>Overall survival was defined as the time to death from the start of panitumumab administration was tabulated.</description>
          <population>All participants that received panitumumab monotherapy as a third-line or later therapy.</population>
          <units>weeks</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1061"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41" lower_limit="36" upper_limit="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>For up to 42 weeks</time_frame>
      <desc>Serious adverse events were tabulated dividing into 2 groups: panitumumab monotherapy or concomitant administration of panitumumab and chemotherapy Serious adverse events grouped by organ system, with number and frequency of such events.</desc>
      <group_list>
        <group group_id="E1">
          <title>Panitumumab</title>
          <description>Panitumumab 6 mg/kg, intravenous drip infusion over a 60-minute period, once every 2 weeks for up to 42 weeks</description>
        </group>
        <group group_id="E2">
          <title>Concomitant Administration of Panitumumab and Chemotherapy</title>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA/J ver. 15.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="614" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="747" subjects_at_risk="1831"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Disseminated intravascular coagulation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Granulocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Bone marrow failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1831"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Unstable angina</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Prinzmetal angina</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Ventricular fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1831"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1831"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Periorbital oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Ulcerative keratitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1831"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Diverticulum intestinal haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Duodenal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Duodenal perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Enterocolitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Gastric ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Gastrointestinal perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Glossitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Glossodynia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Ileal perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Malaena</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Oesophageal varices haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Small intestinal performation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Subileus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Lower gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Large gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Gastrointestinal inflammation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Oral mucosa erosion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Ileal fistula</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Oral mucosal erythema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1831"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Gait disturbance</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Device occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1831"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Cholangitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Cholestasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Hepatic failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Hepatic function abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Jaundice</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Jaundice cholestatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Liver disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1831"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Anaphylactic shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1831"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Endocarditis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Fungaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Herpes virus infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Liver Abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Lung abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Necrotizing fasciitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Paronychia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Pseudomembranous colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Staphylococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Neutropenic infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Abdominal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Pneumocystis jiroveci pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Device-related infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Enterocolitis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Infectious peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1831"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Fractured ischium</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Vascular pseudoaneurysm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Cervical vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Lumbar vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Thoracic vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Infusion related reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Pubis fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1831"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Blood calcium decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Blood magnesium decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Blood potassium increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>C-reactive protein increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Electrocardiogram QT prolonged</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Platelet count descreased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>White blood cell count decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>White blood cell count increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1831"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Diabetic ketoacidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Hyperammonaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Hypercalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Tetany</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Hypophagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1831"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Pathological fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Rhabdomyolysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Spondylitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1831"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Bile duct cancer recurrent</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Malignant ascites</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Metastases to bone</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Metastases to liver</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Lymphangiosis carcinomatosa</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Cancer pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Metastases to central nervous system</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Colorectal cancer</sub_title>
                <counts group_id="E1" subjects_affected="524" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="557" subjects_at_risk="1831"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Altered state of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Bulbar palsy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Cerebellar haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Dysarthria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Hepatic encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Intracranial aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Peripheral neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Paralysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Thrombotic stroke</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1831"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Completed suicide</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1831"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Cystitis haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Renal disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Urinary bladder haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1831"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Interstitial lung diseases</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Pulmonary artery thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract inflammation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Organizing pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1831"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Dermatitis acneiform</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Erythema multiforme</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Henoch-Schonlein purpura</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Oculomucocutaneous syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Purpura</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Rash generalised</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Skin chapped</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Skin erosion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1831"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic dissection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Venous thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Venous thrombosis limb</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1831"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA/J ver. 15.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="640" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="1084" subjects_at_risk="1831"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="155" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="123" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="463" subjects_at_risk="1831"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Paronychia</sub_title>
                <counts group_id="E1" subjects_affected="269" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="458" subjects_at_risk="1831"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" subjects_affected="218" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="198" subjects_at_risk="1831"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" subjects_affected="81" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="112" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Dermatitis acneiform</sub_title>
                <counts group_id="E1" subjects_affected="617" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="959" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="265" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="344" subjects_at_risk="1831"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="98" subjects_at_risk="1254"/>
                <counts group_id="E2" subjects_affected="160" subjects_at_risk="1831"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The present specified drug-use survey is a one-arm observational study with no control group. Therefore, the observed outcome measures provide exploratory information regarding these endpoints; however, do not constitute verification results.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Medical Director, Clinical Science</name_or_title>
      <organization>Takeda</organization>
      <phone>800-778-2860</phone>
      <email>trialdisclosures@takeda.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

